Roots Analysis

SEPTEMBER 1, 2023

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

DECEMBER 9, 2020

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Roots Analysis

OCTOBER 2, 2023

Additionally, it increases the bioavailability and solubility of the attached molecule. In fact, in the last twenty years, the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) have authorized the market approval of around 80 nanomedicines.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Marketing 40

XTalks

FEBRUARY 3, 2023

Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

pharmaphorum

MAY 5, 2021

Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines. . However, Pfizer has a plan to get the franchise back on track, as it also faces the risk of a competitor reaching the market from Merck & Co.

Vaccination 104

Vaccination Vaccine Sales Bioavailability 104

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Nov. Finnish time.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

MARCH 8, 2021

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials In-Vivo Genotoxicity RNA 69

Drug Discovery World

JULY 25, 2023

PIPs are mandatory for applicants seeking marketing authorisation for new medicines in the EU. The voluntary pilot scheme will start with eight sPIPs and will target medicines where elements of the PIP cannot be defined. They are required for orphan drugs but not for biosimilars.

Development 52

Development Drugs Medicine Production 52

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. HELSINKI , Jan.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 SAN DIEGO, Dec. About Kura Oncology.

Bioavailability 52

Bioavailability Containment Sales Medicine 52

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. Several compounds are being further optimized for preclinical studies. Details can be found at this link.

Development 40

Development Bioavailability Production Drugs 40

Delveinsight

SEPTEMBER 8, 2021

The risk factors for SLE include the medicines that induce lupus, age, race/ethnicity, and family history. It is also available as a generic medicine. As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Anifrolumab (MEDI-546).

Marketing 52

Marketing Sales FDA Approval Antibody 52

The Pharma Data

DECEMBER 3, 2020

Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. About Maribavir.

Drugs 52

Drugs Medicine Trials Containment 52

The Pharma Data

MARCH 11, 2021

Last May, Lilly’s first-in-class oral precision medicine, Retevmo received Accelerated Approval from the U.S. Presentation Title: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Portfolio Highlights. Abstract Number: 1236. Retevmo is an U.S.

Research 52

Research Clinical Trials Clinical Trials Trials 52

Drug Discovery World

DECEMBER 7, 2022

By Dr Natalia Dadivanyan , Segment Marketing Manager, Malvern Panalytical . Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. Small molecules can face big challenges .

Bioavailability 52

Bioavailability Manufacturing Production Development 52

Pharmaceutical Technology

NOVEMBER 24, 2022

We asked them to explain how the company has integrated its isotopic labeling and human ADME testing services to help streamline the drug development process and accelerate the time it takes to get drugs to market. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

Drug Discovery World

AUGUST 9, 2023

The development of Ritonavir Ritonavir is a drug for the treatment of Acquired Immuno-Deficiency Syndrome (AIDS) marketed in 1996.

Research 52

Research Bioavailability Scientist Drugs 52

Pharmaceutical Technology

AUGUST 3, 2022

Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market. Today, they are still thought to represent approximately two-thirds of all medicines administered through prescription and over-the-counter. The Frewitt Technology Centre is your address for process development.

Development 130

Development Production Manufacturing Bioavailability 130

The Pharma Data

DECEMBER 1, 2020

The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is covered by more than 93 issued U.S. and international patents which provide protection out to 2040. Axsome Therapeutics, Inc.

Trials 52

Trials Clinical Trials Clinical Trials Production 52

The Pharma Data

APRIL 11, 2023

Notably, these presentations include new data from dose proportionality and bioequivalence studies, which supported the FDA approval of once-daily AUSTEDO XR extended-release tablets – demonstrating AUSTEDO XR is therapeutically equivalent to the currently marketed twice-daily AUSTEDO. Source link: [link]

Bioequivalency 40

Bioequivalency FDA Approval Bioavailability Medicine 40

Drug Discovery World

JANUARY 24, 2024

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. MT: You have been a key driver of the research and development programs of four approved medicines: Prezista, Olysio, Jyseleca and Rekambys. Biography Piet Wigerinck is a pharmacist and holds a PhD in medicinal chemistry from the KU Leuven.

Research 59

Research Gene Expression Drugs Development 59

The Pharma Data

JANUARY 27, 2021

Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine. About XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Pharmaceutical Technology

JUNE 26, 2022

Understanding the polymorphism of a drug compound plays a key role in both drug substance and drug product development, because it can negatively impact the downstream stability, solubility, and bioavailability of a drug. Streamlined processes to reduce time to market for drugs. Integrated drug substance and drug product services.

Manufacturing 130

Manufacturing Drugs Production Development 130

XTalks

AUGUST 30, 2022

CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. Targeting the CNS directly has been successful in modern medicine. Why is it Difficult to Develop CNS Therapeutics?

Trials 83

Trials Drug Delivery Drugs Gene 83

Drug Discovery World

FEBRUARY 2, 2023

Other such transitions have been made internationally in recent years, namely the measures put in place by the European Medicines Agency (EMA) in 2021 to encourage and accelerate the development and adoption of non-animal methods in the testing and approval of new human drugs 4.

Drugs 52

Drugs Clinical Trials Clinical Trials Cosmetics 52

The Pharma Data

MAY 14, 2021

And the unique Japanese mushroom trio – Maitake, Reishi and Shiitake- which were proven to have incredible health properties by one study in the Journal of Oxidative Medicine and Cellular Longevity! Frank Neal is a pen name used for marketing purposes and to protect the author’s identity.

Packaging 52

Packaging Packaging Production Bioavailability 52

The Pharma Data

NOVEMBER 17, 2020

LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Photo: Business Wire). PureTech is also advancing LYT-100 for the treatment of IPF and is actively planning additional PK and dosing studies. About PureTech Health.

Production 52

Production Trials Bioavailability Drugs 52

The Pharma Data

MAY 16, 2021

and could change how “bioavailable” the all-important EBM triggering nutrients are. Bioavailable is a word that scientists use to describe how easy it is for your body to use a nutrient…. Had many different fermentation methods that people used to preserve foods.

Production 52

Production Containment Research Doctors 52